PulseAPI SmartWatch
PulseAI, Ltd. · Decision date Oct 27, 2026
What did the FDA decide?
PulseAI, Ltd. received a substantially equivalent (SESE) decision for the PulseAPI SmartWatch under 510(k) K254226, dated October 27, 2026, with the FDA record listing a receipt date of December 29, 2025. The device is a Class II programmable diagnostic computer (21 CFR 870.1425, product code DQK) in the cardiovascular specialty. It is a software analysis library, not a standalone monitor, that receives ECG waveform data and metadata from lead I or lead II wet-electrode recordings or compatible dry-electrode devices and is meant to be integrated into other device software.
The submission names the AliveCor KardiaAI V2 (K201985) as predicate. The summary states the subject device has the same intended use and similar technological characteristics, with differences addressed through performance testing, including analyses using ANSI/AAMI EC57 reference datasets. SESE is a clearance, not a PMA approval. The indications exclude patients with pacemakers or other implanted electronic devices and exclude life-supporting or alarm-system use. The summary does not disclose quantitative performance results, so the basis for equivalence cannot be independently assessed from these documents.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 27, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K254226
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- PulseAI, Ltd.
- Product code
- DQK
- Decision code
- SESE
- Decision date
- Oct 27, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Computer, Diagnostic, Programmable.
- Applicant
- PulseAI, Ltd.
- Product code
- DQK
- FDA device class
- 2
FDA decision timeline
K254226 received
Application receipt date recorded by FDA.
K254226 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code DQK
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Merge Healthcare Incorporated | 510(k) clearance | Nov 5, 2026 | FDA | |
VIVO (9002)K261886 | Catheter Precision, Inc. | 510(k) clearance | Oct 30, 2026 | FDA |
STAR Apollo Mapping SystemK263380 | Rhythm AI, Ltd. | 510(k) clearance | Oct 23, 2026 | FDA |
| Centerline Biomedical | 510(k) clearance | Oct 1, 2026 | FDA | |
S-Patch CardioAIK254255 | Wellysis Corp. | 510(k) clearance | Sep 25, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
PulseAI, Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Belfast
Sources and methodology
- Original FDA record: K254226
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


